Mortality and risk factors among Israeli bullous pemphigoid patients

被引:0
作者
Mati Rozenblat
Awad Halaj
Tal Rozenblat
Shani Fisher
Mohammad Sah
Roni P. Dodiuk-Gad
Michael Ziv
机构
[1] Emek Medical Center,Department of Dermatology
[2] Tel Aviv University,Sackler Faculty of Medicine
来源
Archives of Dermatological Research | 2019年 / 311卷
关键词
Bullous pemphigoid; Pemphigoid; Mortality; Prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
There are differences concerning reported mortality rates and prognostic factors of bullous pemphigoid (BP) patients in different studies. Our objectives were to evaluate the mortality rates and prognostic factors among Israeli BP patients compared to matched control subjects. Three age- and sex-matched patients without BP (n = 261) who were treated in our clinic were selected and compared to BP patients (n = 87). Mean survival period of the BP group was 4.1 years (95% CI: 3.3–4.8 years) and 5.9 years among the non-BP group (95% CI: 5.6–6.3 years). The 1-year mortality rate was 24.1% for the BP group and 6.5% for the control group. In multivariate analysis, age above 80 was a significant risk factor for mortality [HR 3.22 (95% CI, 1.15–8.96), p = 0.03], while statins intake had a protective role [HR 0.36 (95% CI, 0.15–0.88), p = 0.03]. In univariant analysis, dementia [HR 2.44 (95% CI, 1.02–5.99), p = 0.04] was a risk factor. In conclusion, BP patients’ mortality is correlated to increasing age at diagnosis, dementia, and statins use. Statins’ protective role is newly discussed in the literature.
引用
收藏
页码:19 / 27
页数:8
相关论文
共 190 条
  • [1] Bastuji-Garin S(2011)Risk factors for bullous pemphigoid in the elderly: a prospective case-control study J Invest Dermatol 131 637-643
  • [2] Joly P(1995)Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous diseases French study group Arch Dermatol 131 48-52
  • [3] Lemordant P(2014)A population-based study of the association between bullous pemphigoid and neurologic disorders J Am Acad Dermatol 71 1191-1197
  • [4] Sparsa A(2014)Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009 J Am Acad Dermatol 71 92-99
  • [5] Bedane C(1995)Cloning and characterization of the neural isoforms of human dystonin Genomics 29 777-780
  • [6] Delaporte E(2005)Why Is the mortality of bullous pemphigoid greater in Europe than in the US? J Invest Dermatol 124 xx-xxi
  • [7] Roujeau JC(2017)Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial Lancet Neurol 16 591-600
  • [8] Bernard P(2004)Mortality rate of bullous pemphigoid in a US medical center J Invest Dermatol 122 1091-1095
  • [9] Guillaume JC(2011)Mortality of bullous pemphigoid in Switzerland: a prospective study Br J Dermatol 165 368-374
  • [10] Ingen-Housz-Oro S(2007)Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial Rheumatology 46 1560-1565